Page 75 - Read Online

Chi et al. J Cancer Metastasis Treat 2020;6:43 I http://dx.doi.org/10.20517/2394-4722.2020.90 Page 17 of 17

activated T lymphocytes. Anticancer Res 2008;28:379-87.
84. Tanyi JL, Bobisse S, Ophir E, et al. Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer. Sci
Transl Med 2018;10.
85. Beatty GL, O’Hara MH, Lacey SF, et al. Activity of mesothelin-specific chimeric antigen receptor T cells against pancreatic carcinoma
metastases in a phase 1 trial. Gastroenterology 2018;155:29-32.
86. Lord CJ, Ashworth A. BRCAness revisited. Nat Rev Cancer 2016;16:110-20.
87. Golan T, Hammel P, Reni M, et al. Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. N Engl J Med
2019;381:317-27.
88. Kheder ES, Hong DS. Emerging targeted therapy for tumors with NTRK fusion proteins. Clin Cancer Res 2018;24:5807-14.
89. Levy JMM, Towers CG, Thorburn A. Targeting autophagy in cancer. Nat Rev Cancer 2017;17:528-42.
90. Sulzmaier FJ, Jean C, Schlaepfer DD. FAK in cancer: mechanistic findings and clinical applications. Nat Rev Cancer 2014;14:598-610.
91. Bennewith KL, Huang X, Ham CM, et al. The role of tumor cell-derived connective tissue growth factor (CTGF/CCN2) in pancreatic
tumor growth. Cancer Res 2009;69:775-84.
92. Neesse A, Frese KK, Bapiro TE, et al. CTGF antagonism with mAb FG-3019 enhances chemotherapy response without increasing drug
delivery in murine ductal pancreas cancer. Proc Natl Acad Sci 2013;110:12325-30.
93. Picozzi VJ, Pishvaian MJ, Mody K, et al. Effect of anti-CTGF human recombinant monoclonal antibody pamrevlumab on resectability
and resection rate when combined with gemcitabine/nab-paclitaxel in phase 1/2 clinical study for the treatment of locally advanced
pancreatic cancer patients. J Clin Oncol 2018;36:4016.